Emicizumab Prophylaxis for the Treatment of Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Interim Analysis of the HAVEN 7 Study

被引：10
|
作者：
Pipe, Steven W. [1 ]
Collins, Peter [2 ]
Dhalluin, Christophe [3 ]
Kenet, Gili [4 ,5 ]
Schmitt, Christophe [3 ]
Buri, Muriel [3 ]
Jimenez-Yuste, Victor [6 ]
Peyvandi, Flora [7 ,8 ,9 ]
Young, Guy [10 ]
Oldenburg, Johannes [11 ]
Mancuso, Maria Elisa [12 ]
Kiialainen, Anna [3 ]
Chang, Tiffany [13 ]
Lehle, Michaela [3 ]
Fijnvandraat, Karin [14 ]
机构：
[1] Univ Michigan, Ann Arbor, MI 48109 USA
[2] Cardiff Univ, Sch Med, Cardiff, Wales
[3] F Hoffmann La Roche Ltd, Basel, Switzerland
[4] Sheba Med Ctr, Ramat Gan, Israel
[5] Tel Aviv Univ, Tel Aviv, Israel
[6] Univ Autonoma Madrid, La Paz Univ Hosp, Madrid, Spain
[7] Fdn IRCCS CaGranda Osped Maggiore Policlin, Angelo Bianchi Bon Hemophilia, Milan, Italy
[8] Thrombosis Ctr, Milan, Italy
[9] Univ Milan, Milan, Italy
[10] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA
[11] Univ Bonn, Bonn, Germany
[12] IRCCS Humanitas Res Hosp, Rozzano, Italy
[13] Spark Therapeut Inc, San Francisco, CA USA
[14] Univ Amsterdam, Amsterdam, Netherlands
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-157264
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] AKATSUKI 48-Week Interim Analysis: Emicizumab and Immune Tolerance Induction in People with Hemophilia A and Factor VIII Inhibitors
    Matsushita, Tadashi
    Suzuki, Nobuaki
    Nagae, Chiai
    Nagao, Azusa
    Ando, Masahiko
    Kuwatsuka, Yachiyo
    Nosaka, Daisuke
    Kyogoku, Yui
    Shimura, Tomomi
    Nogami, Keiji
    BLOOD, 2023, 142
  • [32] Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial
    Pipe, Steven W.
    Collins, Peter
    Dhalluin, Christophe
    Kenet, Gili
    Schmitt, Christophe
    Buri, Muriel
    Jimenez-Yuste, Victor
    Peyvandi, Flora
    Young, Guy
    Oldenburg, Johannes
    Mancuso, Maria Elisa
    Kavakli, Kaan
    Kiialainen, Anna
    Deb, Sonia
    Niggli, Markus
    Chang, Tiffany
    Lehle, Michaela
    Fijnvandraat, Karin
    BLOOD, 2024, 143 (14) : 1355 - 1364
  • [33] Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies
    Callaghan, Michael U.
    Negrier, Claude
    Paz-Priel, Ido
    Chang, Tiffany
    Chebon, Sammy
    Lehle, Michaela
    Mahlangu, Johnny
    Young, Guy
    Kruse-Jarres, Rebecca
    Mancuso, Maria Elisa
    Niggli, Markus
    Howard, Monet
    Bienz, Nives Selak
    Shima, Midori
    Jimenez-Yuste, Victor
    Schmitt, Christophe
    Asikanius, Elina
    Levy, Gallia G.
    Pipe, Steven W.
    Oldenburg, Johannes
    BLOOD, 2021, 137 (16) : 2231 - 2242
  • [34] Prevention of Bleeding in Patients with Moderate and Severe Hemophilia A Playing Sports: A Comparison between Factor VIII and Emicizumab Prophylaxis (STEP: SporTs Emicizumab Prophylaxis)
    Chitlur, Meera B.
    BLOOD, 2022, 140 : 5619 - 5620
  • [35] Hemlibra® (Emicizumab) receives EU Approval for Routine Prophylaxis of Hemophilia A with Inhibitors against Coagulation Factor VIII
    不详
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2018, 45 (02)
  • [36] A literature review of major surgery experience with emicizumab in people with hemophilia A without factor VIII inhibitors
    Castaman, Giancarlo
    Croteau, Stacy E.
    Quon, Doris
    Lee, Lucy
    Polito, Letizia
    Jimenez-Yuste, Victor
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2025, 9 (01)
  • [37] Longitudinal dynamic changes in factor VIII inhibitor titers in patients with hemophilia A and inhibitors receiving emicizumab prophylaxis
    Shimonishi, Naruto
    Sasai, Kana
    Ogiwara, Kenichi
    Furukawa, Shoko
    Nakajima, Yuto
    Mizumachi, Kuniyoshi
    Yada, Koji
    Takeyama, Masahiro
    Shima, Midori
    Mizuno, Narumi
    Nogami, Keiji
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 118 (06) : 690 - 698
  • [38] Emicizumab prophylaxis and health-related outcomes in persons with hemophilia a (PwHA) with inhibitors: HAVEN 1 study
    Oldenburg, J.
    Mahlangu, J. N.
    Bujan, W.
    Trask, P. C.
    von Mackensen, S.
    Callaghan, M. U.
    Young, G.
    Asikanius, E.
    Peyvandi, F.
    Santagostino, E.
    Kruse-Jarres, R.
    Negrier, C.
    Kessler, C.
    Levy, G. G.
    Windyga, J.
    Shima, M.
    HAEMOPHILIA, 2018, 24 : 89 - 90
  • [39] Longitudinal dynamic changes in factor VIII inhibitor titers in patients with hemophilia A and inhibitors receiving emicizumab prophylaxis
    Naruto Shimonishi
    Kana Sasai
    Kenichi Ogiwara
    Shoko Furukawa
    Yuto Nakajima
    Kuniyoshi Mizumachi
    Koji Yada
    Masahiro Takeyama
    Midori Shima
    Narumi Mizuno
    Keiji Nogami
    International Journal of Hematology, 2023, 118 : 690 - 698
  • [40] Real-world experience of emicizumab prophylaxis in Korean children with severe hemophilia A without inhibitors
    Kim, Sung Eun
    Kim, Ji Yoon
    Park, Jeong A.
    Lyu, Chuhl Joo
    Hahn, Seung Min
    Han, Jung Woo
    Park, Young Shil
    BLOOD RESEARCH, 2024, 59 (01)
12345